PI vs NNRTI Regimens Face Off in Severely Immunocompromised HIV Patients
A Phase 4 trial compares two antiretroviral strategies in treatment-naive HIV patients with dangerously low CD4 counts below 100.
Summary
This completed Phase 4 clinical trial from Hospital Clinic of Barcelona enrolled 70 treatment-naive HIV patients with CD4 counts below 100 cells per cubic millimeter — a threshold indicating severe immunodeficiency. Researchers compared two antiretroviral regimens: AZT plus 3TC combined with either a protease inhibitor (indinavir boosted with ritonavir) or a non-nucleoside reverse transcriptase inhibitor (efavirenz). The trial examined not only viral suppression in plasma but also in non-plasma compartments such as lymphoid tissue, offering a more complete picture of treatment effectiveness. It also tracked the speed and extent of immune reconstitution, a critical factor for survival in this vulnerable population. Results from this trial could inform which drug class better rebuilds immunity in patients presenting with advanced disease.
Detailed Summary
In HIV care, patients who present with CD4 counts below 100 cells per cubic millimeter represent some of the most medically complex cases. At this level of immune suppression, the risk of opportunistic infections is extremely high, and the urgency to achieve viral suppression and immune recovery is paramount. Choosing the right antiretroviral combination at treatment initiation is therefore a consequential clinical decision.
This completed Phase 4 clinical trial, sponsored by Hospital Clinic of Barcelona, enrolled 70 treatment-naive HIV-positive individuals with CD4 counts below 100 to compare two established antiretroviral backbone strategies. Both arms used AZT and 3TC as the nucleoside analog foundation, differing only in the third agent: a protease inhibitor combination of indinavir and low-dose ritonavir versus the non-nucleoside reverse transcriptase inhibitor efavirenz.
Uniquely, the study assessed virological suppression not only in plasma — the standard measure — but also in non-plasma compartments. These anatomical reservoirs, including lymphoid tissue, can harbor replicating virus even when plasma viral loads appear undetectable, making this a more thorough evaluation of treatment efficacy. Alongside viral outcomes, researchers tracked the kinetics and magnitude of CD4 cell recovery, a direct indicator of immune reconstitution.
The findings have practical relevance for clinicians managing late-presenting patients, a population that remains common in many healthcare settings globally. Understanding which third-agent class produces faster or more durable immune recovery could guide treatment selection in this high-risk group.
However, this summary is based solely on the trial registration abstract, and detailed results, statistical outcomes, and adverse event profiles are not publicly available from this source. The trial was completed, but published findings would be necessary to draw firm clinical conclusions. The relatively small sample size of 70 also warrants caution in generalizing any findings.
Key Findings
- Trial compared PI-based vs NNRTI-based ART in 70 HIV patients with CD4 counts below 100 cells/mm3.
- Viral suppression was assessed in both plasma and non-plasma compartments, capturing hidden viral reservoirs.
- Immune reconstitution kinetics were tracked, measuring how quickly CD4 counts recovered under each regimen.
- Both regimens used the same NRTI backbone (AZT + 3TC), isolating the impact of the third drug class.
- Phase 4 design indicates evaluation of real-world effectiveness after initial regulatory approval of these agents.
Methodology
This was a Phase 4, completed clinical trial enrolling 70 treatment-naive HIV patients with CD4 counts below 100 cells per cubic millimeter. Participants were randomized to AZT+3TC+indinavir/ritonavir or AZT+3TC+efavirenz. Outcomes included virological response in plasma and non-plasma compartments and immune reconstitution kinetics.
Study Limitations
This summary is based on the abstract and trial registration only, as the full study data are not openly available. Detailed efficacy results, adverse event profiles, and statistical analyses cannot be evaluated. The sample size of 70 patients is relatively small, limiting the generalizability of any findings.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.